Progressive multifocal leukoencephalopathy after natalizumab discontinuation

Annals of Neurology

Volumn 75, Issue 1, 2014, Pages 108-115

  Fine, Andrew J ^a   Sorbello, Alfred ^a   Kortepeter, Cindy ^a   Scarazzini, Linda ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; UNITED STATES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84894102134     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24051     Document Type: Article

References (17)

1. Baldwin KJ, Hogg JP,. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 2013; 26: 318-323.
2. Stuve O, Marra, CM, Jerome, KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747.
3. Tysabri. Package insert. Cambridge, MA: Biogen Idec, 2012.
4. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
5. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012; 78: 1390-1393.
6. Moiola L, Sangalli M, Radaelli G, et al. A case of progressive multifocal leukoencephalopathy after discontinuation of natalizumab: when could we let the guard down. Paper presented at: 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; October 21, 2011; Amsterdam, the Netherlands.
7. Roggerone S, Duran-Dubief F, Chenevier F, et al. Remain vigilant after natalizumab discontinuation: three remarkable cases. Paper presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon, France. Abstract P538.
8. Havla J, Berthele A, Kumpfel T, et al. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group." Mult Scler 2013; 19: 1213-1215.
9. Musuka TD, Caroll WM,. Natalizumab-to-fingolimod transition PML and PML-IRIS: management conundrum and insights. Poster presented at: Australian and New Zealand Association of Neurologists Annual Scientific Meeting; October 7, 2012; Perth, Australia.
10. Khatri B, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402-409.
11. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendation for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758.
12. Fox R, Kappos L, Cree B, et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. Mult Scler 2011; 17: S507.
13. Javed A, Rossman H, Reder A, et al. The kinetics of CSF lymphocyte recovery after cessation of natalizumab in patients with multiple sclerosis. Poster presented at: American Academy of Neurology 2010 Annual Meeting; April 10-17, 2010; Toronto, Ontario, Canada; P05.047.
14. Antoniol C, Jilek S, Schlup M, et al. Impairment of JCV-specific T-cell response by corticotherapy. Neurology 2012; 79: 1-7.
15. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
16. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 143-152.
17. Hunt D, Giovannoni G,. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012; 12: 25-35.